KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Long-Term Deferred Tax for 16 consecutive years, with $1.5 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax fell 1.42% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Sep 2025, down 1.42%, and an annual FY2024 reading of $1.5 billion, down 3.65% over the prior year.
  • Long-Term Deferred Tax was $1.5 billion for Q3 2025 at Biomarin Pharmaceutical, up from $1.4 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $1.5 billion in Q1 2024 and bottomed at $1.4 billion in Q2 2025.
  • Average Long-Term Deferred Tax over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 164.71% in 2021, then fell 7.64% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $1.5 billion in 2021, then increased by 3.81% to $1.5 billion in 2022, then rose by 2.68% to $1.5 billion in 2023, then dropped by 3.65% to $1.5 billion in 2024, then rose by 1.33% to $1.5 billion in 2025.
  • Business Quant data shows Long-Term Deferred Tax for BMRN at $1.5 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.5 billion in Q1 2025.